Literature DB >> 18629850

Hollow fiber bioartificial liver utilizing collagen-entrapped porcine hepatocyte spheroids.

F J Wu1, J R Friend, A Lazar, H J Mann, R P Remmel, F B Cerra, W S Hu.   

Abstract

A xenogeneic hollow fiber bioreactor utilizing collagen-entrapped dispersed hepatocytes has been developed as an extracorporeal bioartificial liver (BAL) for potential treatment of acute human fulminant hepatitis. Prolonged viability, enhanced liver-specific functions, and differentiated state have been observed in primary porcine hepatocytes cultivated as spheroids compared to dispersed hepatocytes plated on a monolayer. Entrapment of spheroids into the BAL can potentially improve performance over the existing device. Therefore, studies were conducted to evaluate the feasibility of utilizing spheroids as the functionally active component of our hybrid device. Confocal microscopy indicated high viability of spheroids entrapped into cylindrical collagen gel. Entrapment of spheroids alone into collagen gel showed reduced ability to contract collagen gel. By mixing spheroids with dispersed cells, the extent of collagen gel contraction was increased. Hepatocyte spheroids collagen-entrapped into BAL devices were maintained for over 9 days. Assessment of albumin synthesis and ureagenesis within a spheroid-entrapment BAL indicated higher or at least as high activity on a per-cell basis compared to a dispersed hepatocyte-entrapment BAL device. Clearance of 4-methylumbelliferone to its glucuronide was detected throughout the culture period as a marker of phase II conjugation activity. A spheroid-entrapment bioartificial liver warrants further studies for potential human therapy. (c) 1996 John Wiley & Sons, Inc.

Entities:  

Year:  1996        PMID: 18629850     DOI: 10.1002/(SICI)1097-0290(19961005)52:1<34::AID-BIT4>3.0.CO;2-#

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  5 in total

1.  Interaction between hepatocytes and collagen gel in hollow fibers.

Authors:  Jing Dai; Guo-Liang Zhang; Qin Meng
Journal:  Cytotechnology       Date:  2009-09-27       Impact factor: 2.058

Review 2.  Extracorporeal bioartificial liver for treating acute liver diseases.

Authors:  Ashok Kumar; Anuj Tripathi; Shivali Jain
Journal:  J Extra Corpor Technol       Date:  2011-12

3.  Development of a bioartificial liver employing xenogeneic hepatocytes.

Authors:  W S Hu; J R Friend; F J Wu; T Sielaff; M V Peshwa; A Lazar; S L Nyberg; R P Remmel; F B Cerra
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

Review 4.  Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development.

Authors:  Anurag Mathur; Peter Loskill; Soongweon Hong; Jae Lee; Sivan G Marcus; Laure Dumont; Bruce R Conklin; Holger Willenbring; Luke P Lee; Kevin E Healy
Journal:  Stem Cell Res Ther       Date:  2013-12-20       Impact factor: 6.832

5.  A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems.

Authors:  Juan Lu; Xiaoqian Zhang; Jianzhou Li; Liang Yu; Ermei Chen; Danhua Zhu; Yimin Zhang; LanJuan Li
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.